Search Results

Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced the launch of BKS® Uni, the latest addition to its portfolio of Balanced Knee® implant systems.

GE announced that it has completed its previously announced acquisition of BK Medical, a leader in advanced surgical visualization, from Altaris Capital Partners, LLC.

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the presentation of final results from a Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, being studied for the treatment of BK viremia in adult kidney transplant recipients.

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced positive final results from a Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, being studied for the treatment of BK viremia (BKV) in adult kidney transplant recipients.

Vera Therapeutics, Inc. announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus in kidney transplant patients showed that MAU868 was well tolerated and demonstrated significant BK antiviral activity in kidney transplant recipients with BK viremia.

Memo Therapeutics AG, an innovator in the field of antibody discovery and development, announced the initiation of a phase 1 clinical study targeting BK polyomavirus infection in renal transplant patients.